INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
inMune Bio 2024年第一季度GAAP每股收益美元（0.61美元）未达到预期（0.54美元），销售额为14,000万美元，未达到30.000万美元的预期
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $14.000 thousand which missed the analyst consensus estimate of $30.000 thousand by 53.33 percent. This is a 63.16 percent decrease over sales of $38.000 thousand the same period last year.
InMune Bio（纳斯达克股票代码：INMB）公布的季度亏损为每股0.61美元，比分析师普遍预期的0.54美元（0.54美元）低12.96％。这比去年同期每股亏损0.36美元（0.36美元）下降了69.44％。该公司公布的季度销售额为14,000美元，比分析师普遍预期的3万美元低53.33％。这比去年同期的38,000美元销售额下降了63.16％。